

August 09, 2022

To,
Listing Department
National Stock Exchange Of India Limited,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051
Company Code No. VIJAYA

To,
The Corporate Relations Department
BSE Limited,
Phiroz Jeejeebhoy Towers,
25th floor, Dalal Street,
Mumbai - 400 001
Company Code No. 543350

Dear Sir/Madam,

Sub: Outcome of the Board Meeting.

Ref: Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We hereby inform you that the Board of Directors of the Company at their meeting held today i.e. Tuesday, August 09, 2022 has, inter-alia considered and approved the Un-audited standalone and consolidated financial results of the Company for the first quarter ended June 30, 2022.

The copy of the aforesaid un-audited financial results of the Company together with limited review report(s) of Statutory Auditor are annexed herewith.

The meeting of the Board commenced at 12.00 noon and concluded at 1.20 p.m.

Kindly take the information on record.

Thanking you,
Yours faithfully,
For Vijaya Diagnostic Centre Limited

Anusha Kanumuru Company Secretary

Encl.: As above



BSR&Associates LLP

Chartered Accountants

Salarpuria Knowledge City, Orwell, B Wing, 6th Floor, Unit-3, Sy No. 83/1, Plot No. 02, Raidurg, Hyderabad – 500 081 - India Telephone: +91 40 7182 2000

Limited Review Report on unaudited standalone financial results of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') for the quarter ended 30 June 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')

- We have reviewed the accompanying Statement of unaudited standalone financial results of Vijaya
 Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') ("the
 Company") for the quarter ended 30 June 2022 ("the Statement").
- 2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Attention is drawn to the fact that the figures for the three months ended 31 March 2022 as reported in these unaudited standalone financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
- 5. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Associates LLP

Chartered Accountants

Firm's Registration No.:116231W/W-100024

AMIT KUMAR AMIT KUMAR BAJAJ
BAJAJ
Date: 2022.08.09
12:58:13 +05'30'

Amit Kumar Bajaj Partner

Membership No.: 218685 UDIN:22218685AOPGPC7344

Hyderabad 09 August 2022



Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')

CIN: L85195TG2002PLC039075

Regd. Office: 3-6-16 & 17, Street No. 19, Himayatnagar, Hyderabad-500029, Telangana, India

Corporate Office: No.6-3-883/F, FPA Building, Near Rajiv Gandhi Statute Lane Adjacent to Topaz Building, Hyderabad-500082, Telangana, India

Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Unaudited Standalone Financials Results for the quarter ended 30 June 2022

			Quarter ended		Year ended
		30 June 2022	31 March 2022	30 June 2021	31 March 2022
SI. No.	Particulars	Unnudited	Audited Note 3	Audited	Audited
1	Income		11,374.05	11,933.10	45,087.93
•	(a) Revenue from operations	10,200.77	331.16	325.27	1,291.71
	(b) Other income	292.83	11,705.21	12,258,37	46,379.64
	Total income	10,493.60	11,703.21	12,200,01	
2	Expenses		10	2.051.97	6,895.21
2	(a) Cost of materials consumed	1,268,76	1,747.12	1,565.56	6,867.66
	(b) Employee benefits expense	1,896.78	1,870.96	391.49	1,625.56
	(c) Finance costs	473.63	430.17	1,178.53	5,213.65
	(d) Depreciation and amortisation expense	1,406.88	1,514.46	2,780.85	11,339.48
	(e) Other expenses	3,113.12	3,049.64	7,968.40	31,941.56
	Total expenses	8,159.17	8,612.35	4,289.97	14,438.08
3	Profit before tax [1-2]	2,334.43	3,092.86	4,207.77	1-1,100100
		İ			2 002 00
4	Tax expense	712.00	836.00	1,140.00	3,902.00
	(a) Current tax	(98.28)	(68.71)	(77.72)	
	(b) Deferred tax		(21.39)	-	(21.39)
	(c) Tax pertaining to earlier years	613.72	745.90	1,062.28	3,627.61
	Total tax expense Profit for the period/year [3 - 4]	1,720.71	2,346.96	3,227.69	10,810.47
5	Profit for the periodycar [3-4]				
6	Other comprehensive income				
0	Items that will not be reclassified to profit or loss		i	(0.55)	25.53
	(a) Remeasurement of defined benefit obligations	6.38	33.18	(2.55)	(6.43
	(b) Income-tax relating to above item	(1.61)	(8.35)	·	
	Other comprehensive income (loss) for the period/year (net of tax)	4.77	24.83	(1.91)	
7	Total comprehensive income for the period/year [5+6]	1,725.48	2,371,79	3,225,78	10,023.31
			1,019.66	1,019.66	1,019.60
8	Paid-up equity share capital (Face value of Re. 1 each) (Refer Note 5)	1,020.31	1,019.00	1,512.00	45,978.38
9	Other equity				45,570.50
10	Earnings per equity share (face value of Re. 1 each fully paid up) (Refer	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	Note 5)	1.69	2.30		
	- Basic (in Rs.)	1.68		3.17	10.5
	- Diluted (in Rs.)	1,55	_ 		

- 1. The above standalone financial results of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') ("the Company") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 (the Act') read with the relevant rules thereunder, other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2. The above standalone financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 09 August 2022. The statutory auditors have carried out limited review of the above results for the quarter ended 30 June 2022. An unmodified report has been issued by them thereon.
- 3. The standalone figures for the quarter ended 31 March 2022 are the balancing figures between the audited standalone figures in respect of the full financial year and the published unaudited year to date standalone figures up to the third quarter ended 31 December 2021, which were subject to limited review
- 4. The Company has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".
- 5. During the quarter ended 30 June 2022, the Company has issued 64,832 equity shares of face value of Rs. 1 each on exercise of employee stock options. 6. The Indian Parliament has approved the code on social security, 2020 ("Code") which, interalia, deals with employee benefits during employment and post employment. The code has been published in the Gazette of India. The effective date of the code is yet to be notified. The Company is in the process of evaluating the impact of the relevant
- provisions.

 7. The results of the Company are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com

for and on behalf of the Board of Directors of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')

SURA SURENDRANATH SURENDRANATH REDDY
REDDY Date: 2022.08.09 12.05.02 405'30'

Dr. S. Surendranath Reddy Executive Chairman DIN Number: 00108599

Place: Hyderabad Date: 09 August 2022

BSR & Associates LLP

Chartered Accountants

Salarpuria Knowledge City, Orwell, B Wing, 6th Floor, Unit-3, Sy No. 83/1, Plot No. 02, Raidurg, Hyderabad -- 500 081 - India Telephone: +91 40 7182 2000 Fax: +91 40 7182 2399

Limited Review Report on unaudited consolidated financial results of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') for the quarter ended 30 June 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')

- 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2022 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
- 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Parent

a. Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')

Subsidiaries

- b. Medinova Diagnostic Services Limited
- c. VDC Diagnostics (Karnataka) LLP
- d. Doctorslab Medical Services Private Limited
- e. Medinova Millenium MRI Services LLP
- f. Namrata Diagnostic Centre Private Limited

BSR & Associates LLP

- 5. Attention is drawn to the fact that the figures for the three months ended 31 March 2022 as reported in these unaudited consolidated financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
- Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 7. We did not review the interim financial results of 2 subsidiaries included in the Statement, whose interim financial results reflect total revenues of Rs. 246.35 lakhs, total net profit after tax of Rs. 29.78 lakhs and total comprehensive income of Rs. 29.78 lakhs, for the quarter ended 30 June 2022, as considered in the unaudited consolidated financial results. These interim financial results have been reviewed by other auditor whose report has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

For B S R & Associates LLP

Chartered Accountants

Firm's Registration No.:116231W/W-100024

AMIT

Digitally signed by AMIT KUMAR BAJAJ **KUMAR** Date: 2022.08.09 12:59:04 +05'30'

BAJAJ

Amit Kumar Bajaj

Partner

Membership No.: 218685

Hyderabad 09 August 2022

UDIN:22218685AOPGWY4614



Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') CIN: L85195TG2002PLC039075

Regd. Office: 3-6-16 & 17, Street No. 19, Himayatnagar, Hyderabad-500029, Telangana, India Corporate Office: No.6-3-883/F, FPA Building, Near Rajiv Gandhi Statute Lane Adjacent to Topaz Building, Hyderabad-500082, Telangana, India Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Unaudited Consolidated Financials Results for the quarter ended 30 June 2022

(Rs. in Laklis except as stated) Year ended Quarter ended 31 March 2022 30 June 2021 31 March 2022 30 June 2022 SI. Particulars Audited Audited Audited No. Unaudited Note 3 1 Income 46,236.99 11,620.03 12,268.65 10,436.21 (a) Revenue from operations 1.283.06 328.37 319.09 276.93 (b) Other income 47,520.05 12,597.02 11,939.12 10,713.14 Total income 7,149.91 Expenses 2.108.41 1,787.76 1,303.28 (a) Cost of materials consumed 7,065.94 1,614.55 1,919.74 1,947.60 (b) Employee benefits expense 400.26 1,645.03 433.51 476.51 (c) Finance costs 1,192.09 5,268.61 1,528.06 1,417.59 (d) Depreciation and amortisation expense 11,652.13 2,860.11 3,126.88 3,196.01 (e) Other expenses 32,781.62 8,175.42 8,795.95 8,340.99 Total expenses 4,421.60 14,738.43 3,143.17 2,372.15 Profit before tax [1 - 2] Tax expense 3,963.56 1,174.10 842.13 715.37 (a) Current tax (85.11)(283.06)(76.02)(98.92)(b) Deferred tax, net (8.83)(11.30)(c) Tax pertaining earlier years 3.671.67 1,088.99 754.81 616.45 Total tax expense 11,066.76 3,332.61 2,388.36 1,755.70 Profit for the period/year [3-4] 5 Other comprehensive income Items that will not be reclassified to profit or loss (2.77)27.62 35.93 6.38 (a) Remeasurement of the defined benefit obligations (6.96) 0.64 (8,88) (1.61)(b) Income-tax relating to above item (2.13)20.66 27.05 Other comprehensive income (loss) for the period/year (net of 4.77 11,087.42 3,330.48 tax) 2,415.41 1,760.47 Total comprehensive income for the period/year [5+6] Profit for the period attributable to: 10 968 06 3,296.97 2 371 25 1,745.00 Owners of the Company 98.70 35.64 17.11 10.70 Non controlling interests Other comprehensive income attributable to: 20.07 (2.05)26.21 4.77 Owners of the Company (0.08)0.59 0.84 Non controlling interests Total comprehensive income attributable to: 10 988.13 3,294.92 2.397.46 1,749.77 Owners of the Company 99.29 35,56 17.95 10.70 Non controlling interests Paid-up equity share capital (Face value of Re. 1 each) (Refer 1,019.66 1,019.66 1,020.31 1 019 66 Note 5) 45,802.27 Other equity (Not annualised) (Annualised) Earnings per equity share (face value of Re. 1 each fully paid (Not annualised) (Not annualised) up) (Refer Note 5) 10.76 3,23 233 1.71 - Basic (in Rs.) 10.69

2.31

1.70

Diluted (in Rs.)

- 1. The above consolidated financial results of Vijaya Diagnostic Centre Limited (formerly known as 'Vijaya Diagnostic Centre Private Limited') ("the Company") and its subsidiaries (the Company and its subsidiaries together referred to as "the Group") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder, other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2. The above consolidated financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 09 August 2022. The statutory auditors have carried out limited review of the above results for the quarter ended 30 June 2022. An unmodified report has been issued by them
- 3. The consolidated figures for the quarter ended 31 March 2022 are the balancing figures between the audited consolidated figures in respect of the full financial year and the published unaudited year to date consolidated figures up to the third quarter ended 31 December 2021, which were subject to limited review.
- 4. The Group has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".
- 5. During the quarter ended 30 June 2022, the Company has issued 64,832 equity shares of face value of Rs. 1 each on exercise of employee stock options.
- 6. The Indian Parliament has approved the code on social security, 2020 ("Code") which, interalia, deals with employee benefits during employment and post employment. The code has been published in the Gazette of India. The effective date of the code is yet to be notified. The Company is in the process of evaluating the impact of the relevant provisions.
- 7. The results of the Group are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com

for and on behalf of the Board of Directors of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')

SURENDRANA REDDY
TH REDDY
Date: 2022.08.09
12:05:44+05'30'

Dr. S. Surendranath Reddy Executive Chairman DIN Number: 00108599

Place: Hyderabad Date: 09 August 2022